Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel with Androgen Suppression and Radiation in High-Risk Localized Prostate Cancer
NCT00651326Phase 3Terminated
- Sponsor
- Canadian Cancer Trials Group
- Start
- Jun 2008
- Primary completion
- May 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of docetaxel in prostate cancer (PCa) (2 arms), sponsored by Canadian Cancer Trials Group. Primary endpoint: Disease-free survival. Started Jun 2008; status: terminated.
02
Drugs
docetaxel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00651326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00651326.